Core Insights - GSK raised its 2025 sales expectations following third-quarter results that exceeded forecasts, primarily due to double-digit growth in specialty medicines, particularly in HIV and oncology [1] Company Performance - The third-quarter results showcased strong performance, leading to an upward revision of sales expectations for 2025 [1] - Specialty medicines, including those for HIV and oncology, were significant contributors to this growth, indicating a robust demand in these therapeutic areas [1]